Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results

Author's Avatar
May 12, 2022

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and first quarter 2022 financial results.